PatientsVille.com Logo

MANIA and Lithium

PatientsVille

MANIA Symptoms and Causes

Bipolar disorder is a serious mental illness. People who have it go through unusual mood changes. They go from very happy, "up," and active to very sad and hopeless, "down," and inactive, and then back again. They often have normal moods in between. The up feeling is called Mania. The down feeling is depression.

The causes of bipolar disorder aren't always clear. It runs in families. Abnormal brain structure and function may also play a role.

Bipolar disorder often starts in a person's late teen or early adult years. But children and adults can have bipolar disorder too. The illness usually lasts a lifetime.

If you think you may have it, tell your health care provider. A medical checkup can rule out other illnesses that might cause your mood changes.

If not treated, bipolar disorder can lead to damaged relationships, poor job or school performance, and even suicide. However, there are effective treatments to control symptoms: medicine and talk therapy. A combination usually works best.

NIH: National Institute of Mental Health

Check out the latest treatments for MANIA

MANIA treatment research studies

Lithium clinical trials, surveys and public health registries


Find Drug Side Effect reports



Lithium Side Effects

Therapeutic Agent Toxicity (237)
Confusional State (205)
Tremor (179)
Toxicity To Various Agents (167)
Renal Failure Acute (132)
Dehydration (107)
Diarrhoea (106)
Nausea (96)
Nephrogenic Diabetes Insipidus (93)
Blood Creatinine Increased (91)
Dysarthria (87)
Agitation (83)
Mania (80)
Mental Status Changes (78)
Hyperparathyroidism (77)
Asthenia (77)
Dizziness (77)
Fall (72)
Renal Failure Chronic (71)
Vomiting (68)
Insomnia (66)
Disorientation (66)
Fatigue (61)
Gait Disturbance (61)
Bradycardia (61)
Depression (60)
Haemodialysis (57)
Completed Suicide (56)
Suicide Attempt (56)
Anxiety (56)
Somnolence (53)
Depressed Level Of Consciousness (53)
Overdose (52)
Renal Failure (51)
Hypercalcaemia (51)
Delirium (51)
Hypernatraemia (50)
Neuroleptic Malignant Syndrome (49)
Renal Cyst (49)
Hypotension (47)
Nephropathy (46)
Hypothyroidism (45)
Lethargy (45)
Condition Aggravated (45)
Ataxia (44)
Renal Impairment (43)
Coma (41)
Abnormal Behaviour (40)
Dyspnoea (40)
Weight Increased (39)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

MANIA Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Virtual Darkness as Additive Treatment in Mania
Conditions: Bipolar Disorder;   Mania
Interventions: Device: Blue-blocking goggles/screens;   Device: Clear-lensed goggles
Outcome Measures: Change in Young Mania Rating Scale (YMRS) score;   Change in motor activity measured by use of actigraphy, Actiwatch Spectrum device
2 Not yet recruiting Open-Label Study of Latuda for the Treatment of Mania in Children and Adolescents 6-17 Years Old
Conditions: Mania;   Bipolar I;   Bipolar II;   Bipolar Spectrum Disorder;   Bipolar Disorder
Intervention: Drug: Latuda (Lurasidone)
Outcome Measure: Young Mania Rating Scale
3 Recruiting Multimodal Neuroimaging of Treatment Effects in Adolescent Mania
Conditions: Mania;   Bipolar Disorder
Interventions: Drug: Quetiapine & Placebo;   Drug: Lithium and Placebo;   Other: Healthy Controls
Outcome Measure: The purpose of this study is to use magnetic resonance imaging (MRI) to examine brain structure, function and chemistry in people with Bipolar I disorder (manic or mixed episodes) who are being treated with either quetiapine or lithium.
4 Unknown  Methylphenidate for the Treatment of Acute Mania
Condition: Mania
Interventions: Drug: methylphenidate;   Drug: Placebo
Outcome Measures: manic symptoms as assessed by the Young Mania Rating Scale (YMRS);   EEG-vigilance as assessed by the Vigilanz Algorhithm Leipzig (VIGALL);   movements as assessed by actimetry;   cognitive performance as assesd with the Screen for Cognitive Impairment in Psychiatry (SCIP)
5 Unknown  Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features
Conditions: Bipolar Disorder;   Schizoaffective Disorder
Interventions: Drug: Olanzapine;   Drug: Lithium;   Drug: Chlorpromazine
Outcome Measures: Safety;   ¨The frequency of treatment-emergent adverse events (events that first appear or worsen during the study period) will be compared between both groups.;   ¨The frequency of side effects as rated with the UKU scale will be compared between both groups.;   ¨Weight gain will be compared between both groups.;   ¨Frequency of changes in vital signs and laboratory findings will be compared between both groups.;   Subjective well being;   ¨Total scores on the DAI and the SWN will be compared between both groups.;   Adherence;   ¨Degree of adherence to the treatment as scored on the MARS will be compared between both groups.;   Efficacy;   ¨End point analysis: Mean change in various scales from baseline to week 4 and week 8 will be used to compare the efficacy of the two treatments:;   ¨Primary efficacy analysis will be assessed by comparing the mean change in theYMRS total score.;   ¨Secondary efficacy analysis will be assessed by comparing the mean change in CGI-BP total score and in BPRS total score.;   ¨Response analysis: Response is defined as at least a 50% drop in the total YMRS total score from base line to the 8-weeks end point. Euthymia is defined as a total score on the YMRS of no greater than 12 at end point. The number of patients reaching bot;   Incidence of depressive episodes;   ¨A worsening in the HAMD-21 score of at least 3 points will be used as a definition of a clinically detectable worsening in depressive symptoms.;   Six and 12 months outcome;   Definition of recovery:;   ¨Syndromic recovery: Eight contiguous weeks [50] during which the patient no longer meets criteria for a manic, mixed, or depressive syndrome. Recovery from each of these syndromes is based on DSM-IV criteria and is operationalised as follows: manic synd;   ¨Symptomatic recovery: Eight contiguous weeks [50] during which the patient experiences minimal to no psychiatric symptoms, operationalized as follows: Young Mania Rating Scale total score of 5 or less, Hamilton depression scale total score of 10 or les;   ¨Relapse: Relapse is defined as the return of symptoms after a remission of less than 8 weeks.;   ¨Recurrence: Recurrence is defined as return of symptoms after recovery.;   ¨Functional recovery: Return to premorbid levels of function for at least 8 contiguous weeks [50]. To assess functional recovery, seven of the nine general items from the Premorbid Adjustment Scale are evaluated at the 6 and 12-month follow-up visit for
6 Recruiting Inositol and Omega-3 Fatty Acids in Pediatric Mania
Condition: Pediatric Bipolar Spectrum Disorders
Interventions: Drug: Omega-3;   Drug: Inositol
Outcome Measures: Improvement in Mania symptoms by change in Young Mania Rating Scale (YMRS);   Improvement in depression symptoms by Children's Depression Rating Scale (CDRS)
7 Unknown  Efficacy and Safety of Utapine vs. Seroquel in Patients With Bipolar Mania
Conditions: Bipolar, Mania;   Utapine;   Seroquel
Interventions: Drug: Utapine;   Drug: Seroquel
Outcome Measure:
8 Recruiting Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania
Condition: Bipolar Disorder
Interventions: Drug: Lithium;   Drug: Valproate;   Drug: Oxcarbazepine;   Drug: Quetiapine;   Drug: Olanzapine;   Drug: Ziprasidone
Outcome Measures: Change from baseline in Young Mania Rating Scale at 2 weeks and 6 weeks;   rate of dropout (treatment discontinuation);   Clinical Global Impressions (CGI) Scale;   Brief Psychiatric Rating Scale;   Global Assessment Scale;   Treatment Emergent Symptom Scale;   Hamilton Anxiety Rating Scale;   Hamilton Depression Rating Scale
9 Unknown  Brain Derived Neurotrophic Factor as a Predictor of Response to Treatment in Bipolar Depression and Mania: 16-weeks Follow-up With Quetiapine XR
Condition: BIPOLAR DISORDER
Intervention: Drug: quetiapine
Outcome Measures: Efficacy of quetiapine as a treatment for acute Mania and depression, and of as a manutence treatment.;   Assess the pharmacodynamics of quetiapine by neurotrophins in blood samples.
10 Unknown  Brain Derived Neurotrophic Factor as a Predictor of Response to Treatment in Bipolar Depression and Mania
Condition: BIPOLAR DISORDER
Intervention:
Outcome Measures: Hamilton depression raing scale and young Mania rating scale;   Serum BDNF levels as predictor of response to treatment
11 Unknown  Bipolar Intervention Study: Cognitive Interpersonal Therapy
Conditions: Mania;   HypoMania;   Bipolar Affective Disorder
Interventions: Other: Cognitive Interpersonal Therapy;   Other: Normal Clinical Care
Outcome Measures: Montgomery Asberg Depression Rating Scale (MADRS) (Montogomery and Asberg, 1979);   Bech-Rafaelsen Mania Rating Scale (BRMS) [Bech et al, 1979];   The Internal State Scale (ISS) (Bauer et al, 1991)
12 Unknown  Treatment of Alcohol Dependence and Comorbid Bipolar Disorder
Conditions: Alcohol Dependence;   Bipolar Disorder;   Depression;   Mania;   Psychosis
Interventions: Drug: Lamotrigine;   Drug: Placebo
Outcome Measures: Percent days of abstinence from alcohol;   Drinks per week, drinking days per week, heavy drinking days per week;   Biomarkers of alcohol use: carbohydrate-deficient transferrin, gamma-glutamyltransferase;   Depression as assessed by scores on the Montgomery-Asberg Depression Rating Scale;   Mania/hypoMania symptoms as assessed by the Young Mania Rating Scale;   Neurocognitive performance (California Verbal Learning Test, Rey-Osterrieth Complex Figure Test, etc.)
13 Unknown  To Evaluate the Efficiency and Safety of Quetiapine Fumarate in the Treatment of Acute Manic Patients With Bipolar Disorder.
Condition: Bipolar Disorder
Interventions: Drug: Quetiapine fumarate;   Drug: Sodium valproate
Outcome Measures: The outcome measure is the change from baseline in YMRS total score at Day 28 (LOCF).;   These changes from baseline in PANSS,MADRS, CGI total score at Day 28.
14 Not yet recruiting Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder
Condition: Bipolar Disorder
Interventions: Drug: placebo oral capsules;   Drug: ziprasidone oral capsules
Outcome Measures: Change from Baseline in Young Mania Rating Scale (YMRS) to week 4;   Clinical Global Impression of Severity (CGI S) score change from baseline.;   Clinical Global Impression - Improvement (CGI-I) score;   Change from Baseline in Young Mania Rating Scale (YMRS) at Weeks 1,2 and 3
15 Recruiting Evaluation of the Genetics of Bipolar Disorder
Conditions: Mania;   Bipolar, Disorder;   Depression;   Mood Disorder;   Schizoaffective;   Manic Depression
Intervention:
Outcome Measure:
16 Unknown  A Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder
Condition: Bipolar Disorder
Intervention: Drug: quetiapine fumarate tablet (Seroquel)
Outcome Measures: The primary efficacy variable for this study is the YMRS total score change from baseline to Day 28 (LOCF).;   To evaluate the effectiveness of quetiapine fumarate;   To evaluate the relationship between the serum brain-derived neurotrophic factor and quetiapine fumarate;   To evaluate the safety and tolerability of quetiapine fumarate
17 Unknown  Longitudinal Study of People Presenting for First Treatment of a Mood Disorder
Conditions: Major Depression;   Bipolar Disorder
Intervention:
Outcome Measure:
18 Recruiting Differentiating Unipolar and Bipolar Depression in Young Adults Using fMRI
Conditions: Bipolar Disorder;   Major Depression
Intervention: Drug: Selective Serotonin Reuptake Inhibitor (SSRI)
Outcome Measures: Hamilton depression rating scale;   Young Mania Rating Scale
19 Recruiting Mood Stabilizer (MS)+ Antidepressant vs MS + Placebo in Maintenance of Bipolar Disorder.
Condition: Bipolar I Disorder
Interventions: Drug: Escitalopram;   Drug: Wellbutrin XL
Outcome Measures: Patients who respond to acute treatment with an antidepressant in combination with a mood stabilizer.;   Does continuing antidepressant treatment for 12 months increase the risk of developing a manic or hypomanic episode?
20 Recruiting Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients
Condition: Bipolar I Disorder
Interventions: Drug: Intramuscular (IM) Depot Aripiprazole;   Drug: Intramuscular (IM) Depot Placebo
Outcome Measures: Time from randomization to recurrence of any mood episode during Double-Bind Placebo Controlled phase;   Proportion of subjects meeting criteria for recurrence of any mood episode(manic, mixed, depressive);   Mean change from randomization to endpoint in the CGI-BP-S (Mania) score;   Time from randomization to recurrence defined by hospitalization for a mood episode.